Clinical observation of oxaliplatin combined with S-1 or paclitaxel liposome in the treatment of advanced gastric cancer / 肿瘤

ABSTRACT

Objective: To observe the clinical efficacy and adverse reactions of chemotherapy with oxaliplatin in combination with either S-1 or paclitaxel liposome as the first-line therapy for advanced gastric cancer. Methods: Ninety-two patients with advanced gastric carcinoma were divided into two groups. In group A (46 cases), oxaliplatin combined with S-1 were administered. In group B (46 cases), oxaliplatin combined with paclitaxel liposome were administered. The shortterm curative effect, progression-free survival (PFS), overall survival (OS) and adverse reactions were observed and compared between the two groups. Results: There were no significant differences in the objective response rate, disease control rate and median PFS between group A and group B (41.3% vs 45.7%, 73.9% vs 71.7%, 5.3 months vs 4.6 months; all P > 0.05). The median OS in group A and group B were 12.2 and 10.2 months, respectively, with a statistically significant difference (P < 0.05). The joint and muscle pain and neutropenia in group B were more severe than those in group A (P < 0.05). Conclusion: These two chemotherapy regimens have the similar clinical efficacy for advanced gastric cancer, but oxaliplatin combined with S-1 could be superior to oxaliplatin plus paclitaxel liposome in OS and tolerance of chemotherapeutic toxicities.